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a  b  s  t  r  a  c  t
We  present  three  transmission  models  of visceral  leishmaniasis  (VL) in the  Indian  subcontinent  (ISC)  with
structural  differences  regarding  the  disease  stage  that provides  the  main  contribution  to transmission,
including  models  with  a  prominent  role  of asymptomatic  infection,  and  ﬁt them  to  recent  case  data
from  8  endemic  districts  in  Bihar,  India.  Following  a geographical  cross-validation  of  the  models,  we
compare  their  predictions  for achieving  the  WHO  VL  elimination  targets  with  ongoing  treatment  and
vector  control  strategies.  All the  transmission  models  suggest  that the  WHO  elimination  target  (<1 new
VL  case  per  10,000  capita  per  year  at sub-district  level)  is likely  to  be met  in Bihar,  India,  before  or  close
to  2020  in sub-districts  with a pre-control  incidence  of  10  VL  cases  per  10,000  people  per  year  or  less,
when  current  intervention  levels  (60%  coverage  of  indoor  residual  spraying  (IRS) of insecticide  and  a
delay  of 40 days  from  onset  of symptoms  to treatment  (OT))  are  maintained,  given  the  accuracy  and
generalizability  of  the existing  data  regarding  incidence  and  IRS  coverage.  In  settings  with  a  pre-control
endemicity  level  of  5/10,000,  increasing  the effective  IRS  coverage  from  60 to  80%  is predicted  to lead
to  elimination  of VL  1–3  years  earlier  (depending  on  the particular  model),  and  decreasing  OT  from  40
to  20  days  to bring  elimination  forward  by  approximately  1 year.  However,  in  all  instances  the  models
suggest  that  L.  donovani  transmission  will  continue  after  2020  and  thus  that  surveillance  and  control
measures  need  to remain  in  place  until the  longer-term  aim of breaking  transmission  is  achieved.
© 2017  The  Authors.  Published  by  Elsevier  B.V.  This  is  an open  access  article  under  the  CC  BY  license
(http://creativecommons.org/licenses/by/4.0/).
1. Introduction
Visceral leishmaniasis (VL), also known as kala-azar, is the
world’s deadliest parasitic disease after malaria (Mathers et al.,
2007). From 2004–2008 there were an estimated 200,000–400,000
cases and 20,000–40,000 deaths per year globally (Alvar et al.,
2012). Historically, most VL cases occur in the Indian subcon-
tinent (ISC), where the causative parasite Leishmania donovani
is transmitted by Phlebotomus argentipes sandﬂies and the dis-
ease is considered to infect humans only (Dinesh et al., 2009;
∗ Corresponding author.
E-mail address: e.lerutte@erasmusmc.nl (E.A. Le Rutte).
1 These authors contributed equally.
Swaminath et al., 1942). However, since 2012, there has been a
signiﬁcant decline in the number of VL cases identiﬁed in the ISC,
attributed usually to interventions and socio-economic improve-
ments (Chowdhury et al., 2014; Anon., 2016; WHO, 2015; Sheets
et al., 2010). The World Health Organization (WHO) has targeted
VL for elimination as a public health problem in the ISC by 2020
(WHO, 2015). This is deﬁned as <1 new VL case per 10,000 capita
per year at sub-district (block) level. In the rest of the world, where
VL is mainly zoonotic and caused by another parasite species, the
WHO has not set any elimination target but aims for 100% detec-
tion and treatment of human cases. Current interventions in the ISC
focus on reducing transmission through vector control, mainly by
indoor residual spraying (IRS) of insecticides, and early detection
and treatment of cases (World Health Organization, 2014). In 2012,
the London Declaration on Neglected Tropical Diseases endorsed
http://dx.doi.org/10.1016/j.epidem.2017.01.002
1755-4365/© 2017 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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the WHO  elimination target on VL and pledged to increase research,
funding, supplies and awareness to combat this disease (Uniting to
Combat Neglected Tropical Diseases, 2012). It has been estimated
that the health and economic gains from reaching the WHO  targets
for VL will be enormous (de Vlas et al., 2016). The governments of
India, Bangladesh, Nepal, Bhutan and Thailand have signed a mem-
orandum of understanding setting an ambitious goal of eliminating
VL as a public health problem (at sub-district level in India and
Bangladesh, and district-level in Nepal and Bhutan) by or before
the end of 2017 (World Health Organization South-East Asia, 2014).
Incidence of VL in Bhutan and Thailand is currently very low and
limited to sporadic cases. Nepal reached the targeted low incidence
level in 2014 and has sustained it for 2 years (WHO, 2015). Even
in Bangladesh and India the target-level incidence was reached in
nearly 90% and 70% of endemic sub-districts respectively by 2015
(WHO, 2015). Nevertheless, to achieve the target in the remaining
endemic sub-districts in India, special attention must be paid to
the state of Bihar, which borders Nepal and accounts for 60–90% of
cases in the ISC (World Health Organization, 2011) and about 80%
of cases and 90% of deaths in India (Anon., 2016). Hence, in this
study we focus on the VL elimination status and control strategies
in Bihar.
Mathematical models capturing disease transmission dynamics
and control measures have proven to be useful tools in predict-
ing the feasibility of achieving elimination targets with existing
strategies (Hollingsworth et al., 2015; Rock et al., 2015; Hirve et al.,
2016; Rock et al., 2016). Deterministic VL transmission models
have been developed previously based on the KalaNet dataset from
Bihar (India) and Nepal (Stauch et al., 2011; Stauch et al., 2014).
More recently, Le Rutte et al. (Le Rutte et al., 2016) published a
set of 3 age-structured model variants, each with individuals from
a different disease stage being the main contributors to transmis-
sion: asymptomatic individuals, previously immune individuals in
whom infection has reactivated, and individuals with post-kala-
azar dermal leishmaniasis (PKDL). A sensitivity analysis for the
duration of immunity was included, as both the disease stage which
contains the main contributors to transmission and the duration
of immunity remain unknown factors in the transmission dynam-
ics of VL (Hirve et al., 2016). Available data on the impact of IRS
on VL incidence suggested that the most accurate predictions are
given by the model variant in which asymptomatic individuals are
the main contributors to transmission, with which elimination of
VL (annual incidence rate of <1 per 10,000 per year) by 2017 was
predicted to be feasible only in settings that experience optimal
IRS (continuously implemented from 2012 onwards) and have a
maximum baseline endemicity of 5–10 VL cases per 10,000 capita
per year. In highly endemic settings (<20 VL cases per 10,000) and
in settings with sub-optimal IRS that are facing challenges with
IRS implementation, coverage and insecticide resistance, additional
interventions will be required (Le Rutte et al., 2016). Chapman
et al. (2015) have recently estimated key epidemiological param-
eters for VL, including the duration of asymptomatic infection and
the proportion of asymptomatic individuals who develop clinical
symptoms, by ﬁtting a multi-state Markov model for the natural
history of VL to serological and case data from a highly endemic
region of Bangladesh (Bern et al., 2007). It was  estimated that
asymptomatic infection lasts 5 months on average and approxi-
mately 1 in 7 asymptomatic individuals progress to VL. However,
the extent to which these parameters depend on geographical loca-
tion, endemicity, and other risk factors remains unclear.
To improve the robustness of predictions of the impact of inter-
vention strategies against VL it is vital to compare and combine the
outcomes of different mathematical modelling approaches, as has
been done previously for HIV (Hontelez et al., 2013; Eaton et al.,
2012; Brisson et al., 2003). Here we present the ﬁrst VL modelling
comparison study in which we compare the predictions from (1)
the VL transmission model variant of those developed by Le Rutte
et al. (2016) that provides the most accurate predictions, (2) a
similar model in which symptomatic individuals are the sole con-
tributors to transmission, and (3) a newly developed transmission
model based on the simpliﬁed model of the natural history of VL
presented by Chapman et al. (2015). The three models were ﬁtted
to VL case data collected by CARE India in 2012 and 2013 from 8
endemic districts in Bihar, India (Das et al., 2016; Jervis et al., 2017),
that are currently under intensive vector control with IRS. The mod-
els were compared via their predictive ability in a geographical
cross-validation. The models were then used to predict whether
the elimination target could be achieved in each district. We  fur-
ther predicted whether the elimination target could be achieved in
settings with different pre-control endemicity levels, using current
and improved interventions.
2. Methods
2.1. Mathematical models
The modelling study described in this paper was performed by
two research groups: Erasmus MC,  Department of Public Health in
Rotterdam, The Netherlands and the Warwick Infectious Disease
Epidemiology Research (WIDER) group, University of Warwick,
United Kingdom.
Erasmus MC  developed two VL models: model E0, in which
symptomatic individuals are the sole contributors to transmission,
and model E1 (the best-performing model from their recent study
(Le Rutte et al., 2016)) in which the main contributors to transmis-
sion are asymptomatic individuals. Supplementary File 4 contains
guidelines to run the R-package ‘VLode’ of their age-structured sys-
tem of ordinary differential equations for visceral leishmaniasis
transmission, which is provided in Supplementary File 5. Warwick
developed model W,  which converts their recent Markov model of
the natural history of VL (Chapman et al., 2015) into a transmission
model with vector population dynamics, in which asymptomatic
individuals are the main contributors to transmission. The MATLAB
code for Warwick model ﬁtting and predictions is provided in Sup-
plementary File 6. A schematic presentation of the three models (E0,
E1 and W)  is given in Fig. 1 and the main model characteristics are
listed in Table 1. The models are all deterministic compartmental
transmission models inspired by an earlier VL transmission model
developed by Stauch et al. (Stauch et al., 2011; Stauch et al., 2014).
In the models, susceptible humans can become asymptomatically
infected when bitten by an infectious sandﬂy. The majority of
infected humans recover without developing clinical symptoms
and only a small proportion develop clinical VL. Symptomatic cases
can receive one or two VL treatments, and in models E0 and E1
treated individuals can develop PKDL after some period of appar-
ent, but not absolute recovery (this putatively recovered stage is
included because some VL cases seem to harbor dormant infection
after treatment which leads to this late post-treatment derma-
tological complication of VL (Ramesh et al., 2015)). Susceptible
sandﬂies become infected when they bite infectious humans (who
may  include asymptomatically infected individuals, symptomatic
cases, treated individuals and PKDL cases), and remain latently
infected for some period before they become infectious to humans.
As an important new aspect, relative to previous VL transmission
models, all models presented here include seasonality in the sandﬂy
density, an important feature in VL transmission dynamics on the
ISC (Singh and Singh, 2009). The differences between the models
are described in detail below.
2.1.1. Erasmus MC models (E0 and E1)
The set of Erasmus MC VL transmission models is deﬁned in
terms of a system of ordinary differential equations (ODE) and
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Fig. 1. Schematic representation of model structures. Model E0 (Erasmus MC)  assumes only symptomatic individuals (red boxes) are infectious towards the sandﬂy. In model
E1  (Erasmus MC)  asymptomatic individuals (yellow boxes) are the main contributors to transmission. The red shaded frame includes individuals that tested positive for
parasite  DNA on a polymerase chain reaction test (PCR+) and the green shaded frame includes individuals that tested positive for anti-leishmanial antibodies on the direct
agglutination test (DAT+), obtained from the KalaNet study. In model W (Warwick University), asymptomatic individuals are the main contributors to transmission.
has been previously described and ﬁtted to data from India and
Nepal (Le Rutte et al., 2016), collected through the KalaNet study
(Picado et al., 2010a). The models include population growth of both
humans and sandﬂies (the populations are assumed to grow at the
same rate in the absence of seasonality and IRS) and age-structure
in human mortality and exposure to sandﬂies. In contrast to the
Warwick model, there are compartments for early and late asymp-
tomatic infection, and early and late recovered stage, to allow the
ﬁtting of these models to prevalence of positivity on the direct
agglutination test (DAT) and/or PCR from the KalaNet study.
In this study, models E0 and E1 have been extended with a
yearly seasonal pattern in sandﬂy density based on seasonal pat-
terns observed in sandﬂy distribution studies in Bihar (Tiwary et al.,
2013; Poché et al., 2011; Malaviya et al., 2014a; Picado et al., 2010b).
Seasonality is implemented via a stepwise function in the sand-
ﬂy birth rate, which is assumed to peak during 3 months of the
year (July–September) (Poché et al., 2011). Full details of the model,
including the description, characterization and calculations of equi-
libria of the system of ordinary differential equations along with
data are provided in Additional File 1 of Le Rutte et al. (2016).
2.1.2. Warwick model (W)
The Warwick VL model (Fig. 1) is very similar in structure to
the models of Stauch et al. (2011, 2014) and Le Rutte et al. (2016),
but with some key simpliﬁcations which have been made for par-
simony, given the available data, and to provide a contrast to
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Table 1
Overview of the main model characteristics.
Model characteristic Erasmus MC Rotterdam Warwick University
Model type Population-based (deterministic, age-structured) Population-based (deterministic, no age structure)
Human disease states Susceptible, early and late asymptomatically infected,
symptomatically infected untreated, ﬁrst-line treatment,
second-line treatment, post kala-azar dermal leishmaniasis
(PKDL), putatively recovered, and early and late recovered.
Susceptible, asymptomatically infected, symptomatically
infected, ﬁrst-line treatment, second-line treatment,
recovered.
Sandﬂy  states Susceptible, latently infected, infectious Susceptible, latently infected, infectious
Main contributors to transmission E0) Symptomatic cases
E1) Asymptomatic individuals
Asymptomatic individuals
Interventions considered Vector control (IRS) and decreasing the duration of onset
of symptoms to treatment (OT)
Human demography Per capita birth rate and age-speciﬁc mortality rates (2011) Population based on Indian 2001/2011 census, birth and
mortality rates.
Human sandﬂy exposure Age-dependent, seasonal Seasonal
Distribution of duration of states Exponential Exponential except for duration of symptomatic VL, for which
Erlang-2 distributions were ﬁtted to onset-to-treatment time
distributions in data
the Erasmus MC  models. The main difference is that it does not
include PKDL and dormant infection (in which the individual still
harbors a small number of parasites but is no longer infectious)
following asymptomatic infection or VL treatment. Pathways for
disease progression in the models are essentially the same, but
there is only one compartment for asymptomatically infected indi-
viduals instead of two (for early and late stages), and recovered
individuals are not differentiated by whether they have recov-
ered from asymptomatic or symptomatic infection, or whether
they are still seropositive or not (they are all combined into one
recovered class). The latter simpliﬁcation is made as the model
is only ﬁtted to the CARE data, which contains no information
on individuals’ serological status, and because VL patients’ para-
site loads decrease rapidly following successful treatment (Verma
et al., 2010; Sudarshan et al., 2011), supporting the view that
sandﬂy infection rates from treated patients and individuals who
have recovered from asymptomatic infection are both negligible,
as assumed in the Stauch and Erasmus MC  models. The compart-
mental structure of the human part of the model is inspired by that
of the Markov model developed by Chapman et al. (Chapman et al.,
2015). As individuals’ onset-to-treatment (OT) times are included
in the data, Erlang distributions (Gamma  distributions with integer-
valued shape parameters) are ﬁtted to the OT time distributions for
each district, and different numbers of compartments for clinical
VL used for each district according to the shape parameter of the
Erlang distribution (Mubayi et al., 2010). The model also includes
seasonality in the sandﬂy population via sinusoidal forcing of the
sandﬂy birth rate, such that the sandﬂy population varies seasonally
about a constant mean. A constant human population is assumed
(so the mean sandﬂy-to-human ratio (SHR) remains constant), and
the model does not include human age-structure. Full details of
the model, including the differential equations used to describe
the transmission cycle and the seasonality function, are given in
Supplementary File 1 (SF1).
2.2. Data
Both teams used longitudinal data on numbers of identiﬁed
cases from the CARE study: Erasmus MC  to ﬁt the IRS efﬁcacy (the
factor that together with the IRS coverage determines the impact
of IRS on the SHR) (E0 and E1) and Warwick to ﬁt the SHR (W).
Models E0 and E1 were also ﬁtted to serological population data
from the KalaNet study (Picado et al., 2010a) to estimate biological
parameters, and to additional epidemiological data (Thakur et al.,
2013) to estimate the pre-control SHR. An overview of the CARE,
KalaNet and additional epidemiological data and the ﬁtting process
for each model is provided in Fig. 2.
2.2.1. Identiﬁed cases
In 2013, CARE India collected data on 6081 VL cases in 8 dis-
tricts in Bihar – Saharsa, East Champaran, Samastipur, Gopalganj,
Begusarai, Khagaria, Patna and West Champaran – for an 18-month
reference period for their diagnoses from January 2012 to June
2013. The cases were mainly identiﬁed from the medical records of
public health facilities (primary healthcare centres, and sub-district
and district hospitals), though roughly 15% were referred by other
patients, relatives, accredited social health activists and private labs
and doctors/hospitals. The house of each case was visited and the
VL patient or a relative was interviewed twice to obtain informa-
tion about the case. Individual-level data collected included the
following, all of which are used in this study: age, district, sub-
district, date of onset of symptoms, date of diagnosis, times from
onset to ﬁrst and (if applicable) second VL treatment, type and
duration of treatment, occurrence of a relapse, PKDL, and details
of IRS spraying in the patient’s house and neighborhood. All data
were anonymized after collection. Also, data about various socio-
economic factors, such as caste, house type and construction, and
cattle ownership were collected. These data are not used for our
study but are described in more detail by Jervis et al. (Jervis et al.,
2017). Table S1 in Supplementary File 2 (SF2) shows the burden of
identiﬁed VL cases for each district, and Fig. S1 in SF2 the monthly
numbers of onsets of VL symptoms in each district from January
2012 to June 2013. The latter is the data from the CARE study to
which the three models are ﬁtted. A seasonal pattern in onset of
symptomatic VL cases can be identiﬁed, comparable to what has
been found in other VL datasets (Malaviya et al., 2011). Further
description of the CARE data and how it is used to parameterize the
models is provided in SF2.
2.2.2. Additional epidemiological data
The KalaNet dataset includes age-structured data on DAT and
PCR prevalence and conversion (from negative to positive and vice-
versa) as measured in repeated surveys as well as VL incidence
data monitored continuously amongst 21,267 individuals in Bihar,
India, and Nepal from 2006 to 2009, and infection prevalence in
the sandﬂy population in Nepal (Picado et al., 2010a). PCR data were
collected in a sub-population of individuals aged 15 years and older.
Longitudinal epidemiological data presented by Thakur et al.
(Thakur et al., 2013) on the VL case burden in the 8 CARE districts
show an equilibrium situation of approximately 3 years from 2009
to 2011, before a decline in the number of cases in 2012 towards
those in the CARE data (see Fig. S2 in SF2). These data were there-
fore taken as pre-control data on the VL case burden (i.e. data from
before good quality IRS implementation and reductions in delays to
treatment). The average of the annual number of cases per district
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Fig. 2. Schematic representation of the ﬁtting procedure used by the two  groups, representing the data in the white boxes and ﬁtted parameters per model. SHR = sandﬂy-
to-human ratio, IRS = indoor residual spray.
in 2009 and 2010 was used to estimate the pre-control sandﬂy-
to-human ratios for all 8 districts for models E0 and E1. Here, the
model predictions for the incidence of ‘symptomatic treatment 1′
stage were ﬁtted to the data (since the data consisted of numbers
of treated VL cases). This was different for the CARE dataset, for
which the model predicted incidence of ‘symptomatic untreated’
cases was ﬁtted (as the data comprised numbers of onsets of VL
symptoms). For further details see Supplementary File 2.
Parameter values that could not be taken from the CARE data,
KalaNet data, Thakur data or the 2011 Indian Census were obtained
from the available relevant literature.
2.3. Model ﬁtting and comparison
A geographical cross-validation approach was used to test the
models’ abilities to predict the monthly number of cases in each dis-
trict in the CARE data over the 18-month reference period (January
2012–June 2013). This consisted of censoring the data for one dis-
trict, ﬁtting the model to the monthly numbers of VL onsets in the
other 7 districts, and predicting the trend in the monthly numbers
of onsets in the censored district, and then repeating the process
with a different district censored. Different approaches were used
by Erasmus MC  and Warwick to estimate the case numbers in the
censored district. Erasmus MC  (models E0 and E1) ﬁtted the IRS
efﬁcacy jointly across the 7 uncensored districts and used this as
the estimate of the IRS efﬁcacy in the censored district together
with the pre-control district sandﬂy-to-human ratio (SHR) esti-
mated from the Thakur data. Warwick (model W)  ﬁrst estimated
the IRS efﬁcacy for all 8 districts via a parameter uncertainty anal-
ysis (see SF1), then ﬁtted the SHRs for the 7 uncensored districts
and estimated the censored district SHR by linear regression of
the 2012 average district identiﬁed case burdens (Table S1 of SF2)
on the ﬁtted SHRs (see Supplementary File 3 (SF3)). Other data
from the censored district that were used to predict the monthly
number of onsets included the mean OT time for 2012 and 2013,
and the 2012 IRS coverage level. The OT time prior to 2012 was
assumed to be the same as in 2012. In all models, IRS was  assumed
to have started in January 2011 across all districts based on there
being signiﬁcant increases in the reported coverage of IRS with
DDT (dichlorodiphenyltrichloroethane) between 2008/2009 and
2011/2012 (from as low as 12–17% in 2008/2009 to as high as
80–91% in 2011/2012 (Malaviya et al., 2014b; National Vector Borne
Disease Control Programme, 2012; Hasker et al., 2012)). All dis-
trict speciﬁc information is provided in Table S1 of SF2. The three
models are compared on their ability to ﬁt the VL case data for the
8 (censored) districts of the CARE dataset with the geographical
cross-validation approach, using the deviance (twice the difference
in the negative log-likelihoods of the ﬁtted model and a saturated
model that ﬁts the data exactly) between the 18 data points per
district and the model output.
One of the purposes of this study was to evaluate the predictive
power of the models given surveillance data, if these were available
in real time, and, vice versa, to evaluate whether routine surveil-
lance data, together with models ﬁtted to historic data, can provide
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enough information from which to infer key model parameters.
Therefore two approaches were taken. Warwick only used the case
data to ﬁt their model, whereas Erasmus MC  included additional
data to provide more information to ﬁne-tune key epidemiological
parameters. Below we describe the speciﬁc ﬁtting approaches of
both groups, a ﬂow diagram of which is presented in Fig. 2.
2.3.1. Erasmus MC  VL-models
2.3.1.1. Estimation of biological parameters. Model E1 has pre-
viously been ﬁtted to the KalaNet dataset. This resulted in a
relatively long estimated duration of the early asymptomatic stage
of 382 days. This long duration dampens the effect of seasonal sand-
ﬂy abundance on seasonality in VL incidence and therefore seems
less plausible than previously thought, given the strong seasonal
pattern in the newly available CARE dataset (seasonal patterns in
equilibrium for different durations of early asymptomatic stage are
illustrated in Fig. S3 of SF3, years 2010–2011). Because the long
duration of the asymptomatic stage was primarily driven by the
use of both PCR prevalence and incidence data in our previous ﬁt-
ting exercise, here we no longer used the PCR incidence data and
assumed a series of 10 pre-set values for the duration of the early
asymptomatic stage (PCR+/DAT-, of between 112 and 382 days),
of which the longest value is the estimated duration in the pre-
vious study. The 20 sub-models (Models E0 and E1 each with 10
durations of the early asymptomatic stage) were reﬁtted to the
KalaNet dataset to re-estimate the following biological parameters:
the duration of the late asymptomatic stage (PCR+/DAT+), the dura-
tion of the early recovered stage (PCR-/DAT+), the infectivity of the
early and late asymptomatic stage (model E1 only), and the fraction
of asymptomatic individuals that develop clinical VL (VL incidence).
The age-dependent exposure to sandﬂies and the duration of the
late recovered stage of two years (immunity) were chosen based
on the conclusions from the previous paper. A sensitivity analysis
was performed in this study to also explore the impact of assuming
durations of immunity of one and ﬁve years. All literature based
parameter values can be found in Tables 2 and 3, and all ﬁtted
parameters in Table 4 of the results section.
2.3.1.2. Sandﬂy-to-human ratio (SHR). The 20 sub-models were
then ﬁtted to the average VL incidence of 2009 and 2010 from
Thakur et al (Thakur et al., 2013), which we interpreted as an equi-
librium due to the stability of incidence over the given years in the
data, to estimate the district-speciﬁc SHR in the absence of IRS.
2.3.1.3. IRS efﬁcacy. The IRS efﬁcacy was estimated by ﬁtting each
model to the CARE data on the trend in the numbers of cases over
the 18-month period. Within the model, the IRS impact on the
sandﬂy birth rate was deﬁned as the IRS efﬁcacy multiplied by the
district-speciﬁc IRS coverage rate reported in the CARE data (i.e.
the sandﬂy birth rate was multiplied by 1 minus the aforemen-
tioned product). A sensitivity analysis for the start year of IRS was
performed by ﬁtting the model with IRS starting in 2010 and in
2012.
2.3.1.4. Parameter estimation. All parameters were estimated by
maximum likelihood estimation using the BFGS algorithm from
the optim package in R (version 3.3.0). The data-generating pro-
cess for prevalent cases (DAT and PCR positivity) was  assumed to
be a binomial distribution, and that for incident VL cases (VL cases) a
Poisson distribution. We  calculated conﬁdence intervals for biolog-
ical parameter estimates based on the inverse of the Hessian at the
global optimum (i.e. assuming a multivariate normal distribution).
We further calculated the deviance between each sub-model and
a hypothetical, saturated model exactly predicting the data. Based
on the deviance, we selected the sub-models with the duration of
early asymptomatic stage that was closest to the saturated model
(i.e. lowest deviance) for both model E0 and E1. The sub-models
best ﬁtting the data were then used to generate further predic-
tions. More details of the model ﬁtting procedure are presented in
Supplementary File 3.
2.3.2. Warwick VL-model
2.3.2.1. Biological parameters. Values of biological parameters such
as the average duration of asymptomatic infection and duration of
immunity were based on Chapman et al’s (2015) modelling of the
natural history of infection. Other parameter values (for disease
progression and sandﬂy bionomics) were based on estimates from
previous ﬁeld and modelling studies (see Tables 2 and 3). A parame-
ter uncertainty analysis was  performed to estimate the uncertainty
in key transmission parameters (see below).
2.3.2.2. Sandﬂy-to-human ratio (SHR). Model W was ﬁtted to the
CARE data by estimating the average SHR for each district by max-
imum likelihood estimation. The number of new cases in each
month was  assumed to be Poisson distributed, and the full like-
lihood for each district taken as the product of the individual
probabilities of the monthly numbers of cases predicted by the
model.
2.3.2.3. IRS efﬁcacy. IRS was  assumed to increase the sandﬂy death
rate by a percentage equal to the product of the IRS efﬁcacy factor
and the district IRS coverage rate from the CARE study. The model
was ﬁtted both with a ﬁxed IRS efﬁcacy factor (chosen based on
the parameter uncertainty analysis) and assuming no impact of IRS
on the sandﬂy density, and the goodness of ﬁt compared using the
Akaike Information Criterion (AIC = 2k − 2log(L), where k = 8 is the
number of estimated parameters and L is the total likelihood for
the 8 districts) to assess whether IRS may  have had a signiﬁcant
impact on VL transmission.
2.3.2.4. Parameter uncertainty analysis. Given the high degree of
uncertainty in the values of several of the model parameters, a
parameter uncertainty analysis was carried out to determine 95%
conﬁdence intervals for 9 parameters: the SHR, the amplitude
and phase shift of the seasonal variation in the sandﬂy birth rate,
the proportion of asymptomatic individuals who  develop clinical
VL, the average duration of asymptomatic infection, the relative
infectivities of asymptomatic individuals and clinical VL cases,
the duration of immunity and the IRS efﬁcacy factor (see SF1).
Conﬁdence intervals were determined by simulating the model
with 300,000 parameter sets sampled from random uniform dis-
tributions for the parameters and accepting those for which the
likelihood was  not signiﬁcantly different from the maximum like-
lihood according to the likelihood ratio test. Further details of the
model ﬁtting method and parameter uncertainty analysis are pro-
vided in SF1.
2.4. Predictions of future VL trends
We  ﬁrst predict the trends in VL incidence in the 8 CARE dis-
tricts up to 2020 assuming the continuation of the district-speciﬁc
2012 intervention levels, i.e. the same IRS coverage and OT time.
Then we  explore hypothetical scenarios with incidence rates of 10,
5 and 2 VL cases per 10,000 capita per year, since the estimated
VL endemicities at sub-district level from the CARE data in Bihar
in 2012 ranged between 0 and 9.1 VL cases per 10,000 capita per
year. The distribution of sub-district incidences can be found in Fig.
S4 of Supplementary File 2. For these hypothetical scenarios, VL
incidence is predicted for the default scenario of 60% IRS coverage
and 40-day average OT time, and scenarios with an increased IRS
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Table  2
Parameter values and assumptions that are similar across all models.
Parameters Value* Source Reported range Source
Human parameters
Average duration of symptomatic untreated stage (days) District and year
speciﬁc (See SF2)
CARE data N/A N/A
Average duration treatment 1 (days) 28 CARE data N/A N/A
Average duration treatment 2 (days) 28 CARE data N/A N/A
Average duration of putatively recovered stage (months)** 21 (Ramesh et al.,
2015; Uranw et al.,
2011; Rahman
et al., 2010)
21–36 (Ramesh et al.,
2015)
Average duration of PKDL (years)** 5 Expert opinion and
(Ramesh et al.,
2015)
0.5–5 (Ramesh et al.,
2015; Islam et al.,
2013)
Excess  mortality rate among untreated symptomatic cases
(per day)
1/150 Assumption
Excess mortality rate among treated symptomatic cases
(per day)
1/120 Assumption
Fraction of failed ﬁrst-line treatments District-speciﬁc
(See SF2)
CARE data N/A N/A
Fraction of putatively recovered cases that develop PKDL 2.5% CARE data 2.4%–17% (Uranw et al., 2011;
Islam et al., 2013)
Infectivity of symptomatic untreated cases 1 Reference value 0.02–0.42 (Quinnell and
Courtenay, 2009)
Relative infectivity of patients under treatment 1 and 2 0.5 Expert opinion Unknown
Sandﬂy parameters
Average life expectancy of the sandﬂy (days) 14 (Palit et al., 2011) 10–20
Average duration of incubation period in sandﬂies (days)** 5 (Sacks and Perkins,
1985)
4.7–5.1 (Hurwitz et al.,
2011; Hati et al.,
1984; Shortt, 1945)
Sandﬂy biting rate (per day)** 1/4 (Anon., 2016; Hati
et al., 1984)
1/5–1/4 (Anon., 2016;
Hurwitz et al.,
2011; Hati et al.,
1984; Palit et al.,
2011)
Probability of transmission from an infected sandﬂy to
susceptible human
1 Reference value N/A
* Parameter values held ﬁxed in model ﬁtting and predictions unless otherwise stated.
** Ranges given are for average (median) duration based on the literature. Durations treated as exponentially distributed in models.
coverage of 80% and shorter average OT time of 20 days to reﬂect a
further improvement of the control program.
3. Results
3.1. Parameter estimation
Table 4 presents the values of all ﬁtted parameters of models
E0, E1 and W.  With a duration of the early asymptomatic stage of
112 days and shorter the ability of the models E0 and E1 to repro-
duce the KalaNet data rapidly declined. The best ﬁtting sub-models
had a duration of early asymptomatic stage of 202 days (deviances
of all 18 stable sub-models are presented in Table S3 of SF3). With
model E0, the pre-control SHR ranged from 1.84 in West Cham-
paran to 3.92 in Saharsa and with model E1 from 0.35 in West
Champaran to 0.60 in Saharsa. The IRS efﬁcacy is estimated by ﬁt-
ting the two models to all available CARE data points from the 8
districts simultaneously and resulted in a value of 99.9% (Model
E0) and 82.9% (Model E1), which corresponds to a sandﬂy birth
rate reduction of between 49.7% and 59.9% when multiplied by the
average district IRS coverage rate of 60%. The results and interpreta-
tion of the sensitivity analyses for the duration of immunity (1 and
5 years) and the start year of IRS (2010 and 2012) are presented
in Tables S4–7 of SF3. These results suggest that the duration of
immunity is probably close to 2 years, as was assumed in the pre-
vious study (Le Rutte et al., 2016). Further, the selected start year
of IRS in 2011 ﬁtted the data best.
For model W,  an average IRS efﬁcacy value of 0.006, equivalent
to an annual reduction of 9% in the sandﬂy density with an IRS cov-
erage of 60%, was found to give the best ﬁt to the data from a range
of values tested in the parameter uncertainty analysis. The large
discrepancy between the ﬁtted IRS impact of models E0 and E1
(50–60%) and model W (9%) is largely due to the Erasmus MC  mod-
els also including the drop from the Thakur data to the CARE data
in their ﬁtting procedure. Besides this, a greater IRS impact is also
required for models E0 and E1 to reach the short term drop in cases,
due to the longer duration of the asymptomatic stages (270 days in
models E0 and E1 versus 150 days in model W).  The district aver-
age SHRs that were estimated from ﬁtting model W to the CARE
data for each of the 8 districts individually (without censoring) are
also presented in Table 4. The SHRs are positively correlated with
the district average identiﬁed case burdens (compare Table 4 with
Table S1 in SF2 and see Fig. S1 in SF3), ranging from 0.36 in West
Champaran to 0.45 in Saharsa. When model W was ﬁtted under the
assumption that IRS had no impact on incidence, the model was
unable to reproduce the drop (in all districts but West Champaran)
between the ﬁrst peak in the number of cases in 2012 and the sec-
ond peak in 2013 (results not shown). The model only predicted a
very slight drop in the number of cases in each district due to the
decrease in the OT times from 2012 to 2013. Varying the change in
the mean OT time for each district showed that an approximately
10-fold decrease in the time to treatment would be required to
produce the drop in the numbers of cases from 2012 to 2013, a far
greater decrease than observed in the actual OT times for any of the
districts. The AIC value for the model with the IRS efﬁcacy factor of
0.006 taken from the parameter uncertainty analysis was signiﬁ-
cantly lower than for the model with no effect of IRS (AIC = 1082.2
compared to AIC = 1400.8). This suggests that the drop in the num-
bers of cases across the districts was  more likely due to decreases
in the sandﬂy populations, which may  have occurred as a result
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Table 3
Parameter values and assumptions that differ across the models.
Parameter Value Source
Erasmus MC Warwick
Model E0 Model E1 Model W
Birth rate (per 1000/yr) Bihar speciﬁc District-speciﬁc (see
SF2)
Indian 2011 Census
Mortality rate (per
1000/yr)
Bihar speciﬁc,
age-dependent
District-speciﬁc (see
SF2)
Indian 2011 Census
Sandﬂy birth rate Stepwise function with
3 month peak in
July–Sept
Sinusoidal function
with peak in Oct–Nov
(Poché et al., 2011) (E0,
E1) (Picado et al.,
2010b; Kesari et al.,
2014; Ghosh et al.,
1999) (W)
Infectivity of PKDL,
relative to
symptomatic untreated
cases
0.5 0.5 N/A Expert opinion
Duration of immunity
(years)
2 (1 and 5 in sensitivity
analysis)
2 (1 and 5 in sensitivity
analysis)
5 Assumption based on
(Le Rutte et al., 2016)
(E0,E1) Assumption
based on (Chapman
et  al., 2015) (W)
Average duration of
PKDL (years)
5 5 N/A Expert opinion,
(Ramesh et al., 2015)
Sandﬂy exposure Age-dependent Age-dependent N/A (Le Rutte et al., 2016)
Duration of early
asymptomatic stage
(days)
202 202 Early + late = 150 (Le Rutte et al., 2016)
(E0, E1) (Chapman
et al., 2015) (W)
Duration of late
asymptomatic stage
(days)
69 days (ﬁtted) 69 days (ﬁtted)
Infectivity of
asymptomatic stage
0 (pre-set) 0.0114 (early) 0.0229
(late) (ﬁtted)
0.025 Assumption based on
(Stauch et al., 2011)
(W)
Fraction of (late stage)
asymptomatic
individuals who
develop VL
0.0142 (ﬁtted) 0.0142 (ﬁtted) 0.03 Assumption based on
(Hasker et al., 2014)
(W)
of IRS or other extraneous factors, than decreases in the OT times.
However, we note that these results are dependent on the assumed
infectivity of asymptomatic individuals (such that they are the main
contributors to transmission) and the estimated efﬁcacy of IRS.
3.2. Geographical cross-validation
The monthly VL case numbers for each censored district pre-
dicted by the three models in the geographical cross-validation,
together with the observed case numbers from the CARE dataset are
presented in Fig. 3. Models E0 and E1 predict the data of censored
districts Saharsa, East Champaran, Khagaria and West Champaran
relatively accurately. However, in Begusarai and Patna the models
both predict slightly lower numbers of identiﬁed cases compared to
the data and slightly higher numbers in Samastipur and Gopalganj.
For model W,  the SHR for the censored district was  informed solely
by the average case burden in 2012 in the censored district, and
therefore the predictions for the censored districts are less accu-
rate than for models E0 and E1, which are informed by multiple
data points from historical data. As expected given the simplicity
of the estimation method, the ﬁts are better when all the districts
are uncensored (compare Fig. 3 with Fig. S2 in SF3) and the method
suffers from considerable inaccuracy for the lowest burden district
(West Champaran). For Begusarai, the SHR estimated from linear
regression of the 2012 average district case burdens on the ﬁtted
SHRs for the other 7 districts is insufﬁcient to give a stable endemic
equilibrium (i.e. the method predicts zero cases).
3.3. Prediction of elimination
Fig. 4 presents forward predictions of VL incidence up to 2020
for all 8 districts with their district-speciﬁc IRS coverage (2012)
and OT time (2013). Here, the three models were ﬁtted to all of
the available CARE data. Models E0, E1 and W all show that the
target incidence of <1 VL case per 10,000 capita per year will be,
or has already been, reached at district-level in all districts before
2020, apart from Saharsa as predicted by models E0 and E1. In
fact, for Patna and West Champaran the data already indicate an
identiﬁed VL case burden in 2012 below the target of <1 new VL
case per 10,000 population per year. Due to the seasonal variation
in incidence, the predicted incidence for the other districts oscil-
lates above and below 1 VL case per 10,000 capita per year before
decreasing and remaining below the target. We interpreted the
ﬁnal point at which the model predictions pass through the target
incidence line as the district-level elimination time. Models E0 and
E1 predict that Begusarai, Khagaria, East Champaran, Samastipur
and Gopalganj will reach the elimination target between mid-2011
(E1) and 2019 (E0). Model E0 predicts a slower trend towards
elimination compared to model E1, with elimination occurring a
maximum of 3 years later (Gopalganj), due to the slower impact
of interventions caused by symptomatic cases (VL and PKDL) being
the main contributors to transmission as opposed to asymptomatic
individuals. The difference in predictions of reaching the elimina-
tion target between the shortest (142 days) and longest (382 days)
duration of the early asymptomatic stage, ranges between 1 and
3 years, depending on the district, with the longest duration until
elimination predicted by the model with the longest duration of
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Table  4
Estimated parameter values resulting from ﬁtting to all district data without censoring.
Parameter* Erasmus MC  Warwick
Model E0
(95% CI**).
Model E1
(95% CI**)
Model W
1. Fraction of late
asymptomatic individuals who
develop VL (%)
1.42 (1.00–1.84) 1.42 (1.00–1.84) N/A
2.  Duration late asymptomatic
stage (days)
69 (49–119) 69 (49–118) N/A
3.  Duration early recovered
stage (days)
237 (196–299) 236 (196–298) N/A
4.  Infectivity of early
asymptomatic stage
0*** 0.0114**** N/A
5.  Infectivity of late
asymptomatic stage
0*** 0.0229 (0–0.0533) N/A
6.  District speciﬁc average
sandﬂy-to-human ratio (SHR)
Saharsa 3.92 0.604 0.445
East  Champaran 2.20 0.392 0.381
Samastipur 2.49 0.401 0.398
Gopalganj 2.33 0.403 0.390
Begusarai 2.78 0.383 0.425
Khagaria 2.44 0.388 0.401
Patna  2.12 0.359 0.380
West  Champaran 1.84 0.351 0.364
7.  IRS efﬁcacy*****
(Employing data from all 8
districts)
0.999 0.829 0.006
NB. Values for models E0 and E1 presented here are only for the duration of early asymptomatic stage of 202 days; values for the other sub-models are listed in Table S3 of
Supplementary File 3.
* Parameters 1–5 were ﬁtted to the KalaNet data (models E0 and E1), parameter 6 was  ﬁtted to the Thakur data (models E0 and E1) and the CARE data (model W),  and
parameter 7 was ﬁtted to the CARE data (models E0, E1 and W).
** Conﬁdence interval.
*** Pre-set values, in model E0 asymptomatic individuals are considered not to be infective.
**** Not ﬁtted, but calculated as half the infectivity of the late asymptomatic stage.
***** The IRS efﬁcacy is multiplied by the district-speciﬁc IRS coverage rate to get the IRS impact on the SHR. Note, however, that the dependence of the SHR on the IRS efﬁcacy
is  linear in models E0 and E1, but exponential in model W (see Additional File 1 of (Le Rutte et al., 2016) and Supplementary File 1).
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Fig. 3. Geographical cross-validation of the models: predictions for the monthly number of VL cases in each district from ﬁtting the models to the other 7 districts and using
the  ﬁtted models to predict the cases in the censored district. The CARE data are presented with black dots and the lines present the predictions of models E0 (red), E1 (green)
and  W (blue) between January 2012 and June 2013. The prediction of 0 cases for Begusarai for model W is due to the sandﬂy-to-human ratio estimated from ﬁtting to the
other  7 districts giving a basic reproduction number below 1 (so that there is no stable endemic equilibrium).
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Fig. 4. VL incidence predictions for each district employing all of the CARE data. The CARE data are presented with black dots and the lines present the predictions between
2010  and 2020 for each model. IRS starts in January 2011, after which IRS coverage remains constant. The difference in the pre-control endemic equilibrium between the
Erasmus MC and Warwick models is due to Erasmus MC ﬁtting to historical case data from (Thakur et al., 2013) before ﬁtting to the CARE data and Warwick ﬁtting only to
the  CARE data. The black dashed line represents the WHO  elimination target of <1 VL case per 10,000 population per year. The monthly predictions between January 2012
and  June 2013 are also presented in SF3, Fig. S2.
the early asymptomatic stage (Fig. S3 in SF3). Model W predicts
that Begusarai, Samastipur, Khagaria, East Champaran and Gopal-
ganj reached the target between April 2013 and May  2014 (in that
order), and Saharsa in June 2015. The systematic difference in the
pre-control endemic equilibrium between models E0 and E1 and
model W is due to Erasmus MC  ﬁtting to historical annual case
data from Thakur et al. (2013) before ﬁtting to the CARE data and
Warwick only ﬁtting to the CARE data.
As described above, the WHO  elimination as a public health
problem goal is deﬁned as reaching the target at sub-district level,
not at district level. The predicted incidences for three typical sub-
districts with current and alternative intervention strategies are
presented in Fig. 5. In sub-districts with a pre-control endemic-
ity level of 2/10,000, models E0 and E1 predict that elimination
will be reached under the current interventions (an average OT
time of 40 days and 60% IRS coverage) ∼1.5 years after starting
IRS, whereas under the same conditions model W predicts that
elimination will be reached after 3.5 years. In sub-districts with
a pre-control endemicity of 10/10,000, model W predicts reach-
ing the target incidence after 5.5 years, model E1 after 6 years and
model E0 after more than 8 years from the start of IRS. Increas-
ing the IRS coverage from 60% to 80% or halving the OT time from
40 days to 20 days brings forward elimination by 6 months to 3
years at all endemicity levels for all models (the reductions in the
time to elimination being greater for the sub-districts with higher
pre-control endemicities). Models E0 and E1 predict that increas-
ing the IRS coverage to 80% will have a greater effect than halving
the OT time, whereas model W predicts that halving the OT time
will have a slightly greater effect. However, combining an increase
in IRS coverage to 80% with a reduction in OT time to 20 days is
predicted to reduce the time to elimination at all endemicity levels
for all models.
4. Discussion
The Erasmus MC  and Warwick models are quite different in their
model structure, ﬁtting methodologies and use of data, yet their
long-term predictions are comparable and suggest that elimina-
tion can be reached by or shortly after 2020 even in highly endemic
sub-districts (up to 10 VL cases per 10,000 capita per year pre-IRS),
provided IRS started before or in 2011 with a minimum coverage
level of 60% and is maintained at this level, and provided that the
average onset-to-treatment (OT) time does not exceed 40 days. In
settings with a pre-control endemicity level of 5/10,000, increas-
ing the effective IRS coverage from 60 to 80% is predicted to lead
to elimination of VL 1–3 years earlier (depending on the type of
model), and decreasing OT from 40 to 20 days to bring elimination
forward by approximately 1 year.
All VL transmission models face the challenge of describing
transmission of a disease with many key factors, such as the role
of immunity and the contributions of individuals in different dis-
ease stages to transmission, basically remaining unknown (Rock
et al., 2015, 2016; Le Rutte et al., 2016). Also the impact of IRS, the
main intervention strategy, on sandﬂy densities remains debated.
Together, the KalaNet and CARE studies provide information about
the prevalence of leishmania DNA and anti-leishmanial antibodies
in the population, as well as detailed data on start of symptoms,
detection and treatment dates of symptomatic individuals. Since
both studies were conducted in the same region, biological parame-
ters estimated from the KalaNet data were considered to be similar
in the CARE study sites, but this is not necessarily the case. Also,
although longitudinal, the CARE dataset only covered a time period
of 18 months, which is short relative to the long duration between
time of infection and cure of the disease, the time until develop-
ment of PKDL and the potentially long duration of immunity. The
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Fig. 5. VL incidence predictions at sub-district level for different endemic scenarios under alternative intervention strategies. The lines present the VL incidence predictions
for  each model. The black dashed line represents the WHO  elimination target of <1 VL case/10,000 population/year at sub-district level. Interventions start in year 0 after
which  they are continued at the same level. OT denotes the time between the onset of symptoms and the start of treatment, IRS coverage represents the percentage of houses
sprayed, which is multiplied by a (constant) IRS efﬁcacy of 0.999 and 0.829 in models E0 and E1 and 0.006 in model W.  The 12 predictions presented here include 3 different
endemic scenarios of 10, 5 and 2 cases per 10,000 population each with 4 different combinations of interventions.
sensitivity of the sub-district-level model predictions to the esti-
mated reduction in the sandﬂy-to-human ratio due to IRS (9% for
model W,  50% for model E0 and 60% for model E1) demonstrates the
importance of collecting sandﬂy data alongside human epidemio-
logical data to properly quantify the impact of IRS. Furthermore,
the CARE dataset did not provide information about the start years
of IRS per district, sandﬂy bionomics data from the same location
and time period as the VL case and IRS coverage data, or sandﬂy
DDT-resistance data, all important factors to estimate the impact
of IRS strategies on VL incidence. Given the relatively long duration
of the asymptomatic infection stage, the duration of immunity and
the role of PKDL (which could slow down the initial decline seen
in the ﬁrst two years of control (Le Rutte et al., 2016)), the decline
in VL incidence due to IRS is expected to be seen only months to
years after the start of IRS; hence data spanning a longer time frame
would be valuable for future studies.
Both model E0, in which asymptomatic individuals are not
infectious, and model E1, where the main contributors to transmis-
sion are asymptomatic individuals, provided an estimate of about
200 days as the duration of the early asymptomatic stage best ﬁtting
the CARE data (i.e. 9 months when including the late asymptomatic
stage). For model W,  the average duration of asymptomatic infec-
tion was based on (Chapman et al., 2015), where it was  estimated as
approximately 5 months (95% CI 4–5.5 months). This estimate was
used in this paper as it is supported by the presence of a seasonal
pattern in the monthly numbers of VL cases in the CARE districts and
the timing of this pattern relative to observed seasonal variation
in sandﬂy abundance in Bihar (Poché et al., 2011; Malaviya et al.,
2014a; Picado et al., 2010b; Kesari et al., 2014). It also agrees rea-
sonably well with the results of the parameter uncertainty analysis
for model W (the maximum likelihood estimates for the asymp-
tomatic infection duration for the 8 districts ranged from 98 to
163 days, see SF1). Even though the main contributors to transmis-
sion remain unknown, the predictions of models E0 and E1, which
both ﬁt the data nearly equally well, provided new insights in reach-
ing the elimination targets in both (extreme) scenarios. Model W is
comparable to model E1 in terms of asymptomatics being the main
contributors to transmission, but because of differences between
the models in the durations of disease stages and ﬁtting the mod-
els to different data, the ﬁtted IRS impact for model W is much
lower, leading to a slower reduction in incidence with current and
improved interventions. When more information becomes avail-
able regarding the main contributors to transmission, more weight
can be put on the predictions of model E0 or model E1 (or model
W),  which differ most in terms of long-term trends.
Another unknown aspect of the VL dynamics is the role and
duration of immunity. We  therefore repeated our analyses of mod-
els E0 and E1 for two alternative durations of 1 and 5 years. With a
5-year average immunity it was  not possible to ﬁt the sub-models
to the data with an early asymptomatic stage duration shorter than
322 days (which was one of the 10 chosen durations). However, in
our study, we interpreted the KalaNet and Thakur data as endemic
equilibriums, which is not always the case in the ﬁeld when looking
at longitudinal data, especially at local level. We might have arrived
at a different duration of immunity had we  been able to ﬁt our sub-
models to data including ﬂuctuations in incidence over multiple
years at a local level (Bora, 1999; Muniaraj, 2014; Thakur, 2007).
We also performed a sensitivity analysis of models E0 and E1 for
the start year of IRS, for which no conclusive data were available.
We interpreted the start year of IRS in 2011 to be the most likely
scenario when compared to starting IRS in 2010 or 2012, because
of the decrease in VL incidence in multiple datasets after 2011
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(Thakur et al., 2013; State Surveillance Unit, 2012; Independent
Commission on Development & Health in India, 2014), and since
starting IRS in 2012 ﬁtted the data poorly (see SF3).
The ﬁtted IRS efﬁcacy for models E0 and E1 led to a sandﬂy
birth rate reduction between 37% in Gopalganj and 72% in Saharsa,
which aligns with reported reduction in sandﬂy density of 72% after
IRS with DDT (Joshi et al., 2009). For model W,  the IRS efﬁcacy
corresponds to an annual reduction in sandﬂy density of 6.7% in
Gopalganj and 10.7% in Saharsa. This is apparently at odds with
estimates for reductions in sandﬂy densities from ﬁeld studies
(Joshi et al., 2009), but could reﬂect poor implementation of IRS
and increasing sandﬂy resistance to DDT (Coleman et al., 2015).
However, given the correlation of the IRS efﬁcacy factor with other
parameters (e.g. the average duration of asymptomatic infection), it
is also possible that the IRS efﬁcacy factor has been underestimated
due to inaccuracies in the estimates for correlated parameters. The
issue of parameter identiﬁability is not restricted to the IRS efﬁ-
cacy, as the parameter uncertainty analysis for model W in SF1
shows. The average sandﬂy-to-human ratio and the infectivity of
asymptomatic individuals are strongly negatively correlated, and
the average duration of asymptomatic infection and amplitude of
the seasonal forcing of the sandﬂy birth rate are positively corre-
lated for most districts, which means that these parameters cannot
be uniquely identiﬁed from the CARE data, which may  account for
some of the differences between the models’ predictions. Hence,
data from high quality epidemiological and entomological studies
are needed alongside the CARE data to tease apart the correlation
between these parameters. Using more detailed data on disease
progression (e.g. longitudinal serological data for humans and
infection prevalence data for sandﬂies) would then also improve
the accuracy of model predictions (as demonstrated by models E0
and E1).
In model W it was assumed that 3% of asymptomatic individuals
develop clinical symptoms even though the estimated proportion
for the dataset analyzed in (Chapman et al., 2015) was  14.7% (95%
CI 12.6–20.0%). This is because the maximum proportion that the
CARE data can support is 7.3%, assuming an asymptomatic preva-
lence of approximately 1% at district level and a long asymptomatic
duration of 530 days (Le Rutte et al., 2016) (see SF1), and because
more recent studies from Bihar suggest values in the region of 3–4%
(Hasker et al., 2014). This difference in the estimated proportion of
asymptomatics progressing to VL may  reﬂect the different loca-
tions and time periods in which the studies were conducted – the
former in Bangladesh during an epidemic, the latter in Bihar, India,
4–5 years after an epidemic (Hirve et al., 2016). However, due to the
focal nature of VL it is also likely that we have signiﬁcantly under-
estimated local VL incidence from the CARE dataset that all three
models were ﬁtted to, because we calculated the identiﬁed case
burden at district-level, such that a higher proportion of asymp-
tomatic individuals progressing to VL is likely.
Another potential source of inaccuracy in model W is the omis-
sion of PKDL. Including PKDL in the model results in longer times
to elimination, as there is a reservoir of infectious individuals
with potentially long durations of infectivity. However, PKDL was
excluded due to uncertainty regarding the disease history of PKDL
cases and the proportion of individuals with PKDL that were actu-
ally diagnosed.
All models currently assume that there is homogeneous risk of
transmission, but VL occurrence is highly spatially heterogeneous
and at a scale much smaller than that of a district (Bern et al., 2010;
Bhunia et al., 2013). Consequently, we are averaging the incident
cases over the total population of all affected sub-districts regard-
less of how many of those people were at risk of infection, thus
underestimating the incidence in those actually at risk. Models with
ﬁner geographic stratiﬁcation (e.g. at the level of villages or even
sets of households) and migration would present a more realistic
framework and potentially provide an important tool for modelling
elimination of infection. An individual-based model would be able
to include advanced aspects such as these. Less than half of the
8885 villages and town wards in the 8 districts had a VL case during
the study period. However, there may  be signiﬁcant transmission
in villages without cases during the timeframe of the data if the
asymptomatic to symptomatic ratio is as high as estimated, but
this cannot be discerned from the CARE data since it contains no
information on asymptomatic cases.
District- and state-level data on annual case numbers suggest
that there are long-term cycles (with a period of ∼15 years) in
incidence, which are not produced by our models and cannot be
readily explained by them either (Bora, 1999; Muniaraj, 2014;
Thakur, 2007). The models all assume that the transmission dynam-
ics were in equilibrium prior to 2011 and we  did not implement
an underlying mechanism for these ∼15-year cycles in our models
because there are no data explaining such a mechanism. However,
it has been suggested that these cycles have been caused by inter-
mittent control efforts (Muniaraj, 2014). The additional impact of
IRS and reduced OT time over a decrease in incidence from being
in a declining phase of a long-term epidemic cycle (as appears
to be the current situation) is therefore unknown. The potential
role that long-term immunity could play in the epidemic cycles,
by causing rapid depletion of the susceptible pool in the popula-
tion during an epidemic, which is then replenished by births in
the inter-epidemic period, has also not been accounted for (Dye,
1992), given the assumed short durations of immunity (2–5 years).
However, it remains to be shown that such a mechanism could
lead to distinguishable long-term cycles at the level of districts, let
alone countries and subcontinents. Longer time series, and ideally
also serological and PCR data, are needed to accurately estimate
duration of immunity and other key parameters.
Whilst the deterministic compartmental models presented here
are suitable for understanding and predicting the longer time-scale
dynamics and interactions, they are less useful for predicting the
situations close to elimination or after elimination. When numbers
of cases become very small stochastic effects dominate, something
all three models do not account for. Given that recrudescence would
have a signiﬁcant public health impact if not controlled, stochas-
tic models would be very useful. Such models could also be used to
assess the effectiveness of alternative targets. For example, since VL
is such a focal disease, setting targets and focusing interventions at
a smaller (e.g. village) level could be a valuable next step. However,
stochastic (and in particular individual-based or agent-based) mod-
els typically contain more parameters and therefore require more
detailed data and/or assumptions.
Our three models differ in terms of detailed structure and
parameterization. Despite these differences, the models are con-
sistent in predicting that we are on track to reach the target
elimination incidence in all 8 Indian districts – at least at district
level. Several sub-districts were already below the target incidence
in 2012. The 10 sub-districts with the highest endemicity were all
in Saharsa and East Champaran with ≥5 VL cases per 10,000 capita
per year. These sub-districts are likely to require additional efforts,
such as increased IRS coverage and reduced OT time, to reach the
target incidence on time.
Capturing the disease transmission dynamics of visceral leish-
maniasis in a mathematical structure is a complex challenge due
to the many unknown factors regarding this neglected tropical dis-
ease (Hirve et al., 2016; Cameron et al., 2016). However, combining
the outcome of different mathematical modelling approaches cre-
ates a more solid foundation from which to draw conclusions about
reaching the VL elimination targets for the Indian subcontinent. We
caution that a model comparison such as this can provide false con-
ﬁdence as there are processes which are not included in the models
that might be critical. In particular, all the models assume the same
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underlying SIRS structure (susceptible – infected – resistant – sus-
ceptible) and none of the models includes spatial heterogeneity.
Nonetheless, based on the three VL transmission models, we  con-
clude that reaching the VL elimination target of less than 1 VL case
per 10,000 capita at sub-district level before or shortly after 2020 in
the Indian subcontinent seems feasible under continued interven-
tions of indoor-residual spraying and early detection and treatment
of cases.
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